Newswire (Published: Monday, July 22, 2019, Received: Monday, July 22, 2019, 3:56:48 PM CDT)

Word Count: 439

2019 JUL 22 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Women’s Health Daily -- New research on Oncology - Prostate Cancer is the subject of a report. According to news reporting originating in Bari, Italy, by NewsRx journalists, research stated, “: Mutations in the oncosuppressor gene () predispose to aggressive forms of prostate cancer which show poor response to taxane-based therapy, the standard treatment for castration-resistant, aggressive prostate cancer. Herein, we addressed the question whether changes in BRCA2 expression, a potential surrogate marker for BRCA2 activity, may affect the response of castration-resistant prostate cancer cells to 6-thioguanine (6-TG), a thiopurine used in the treatment of haematological malignancies.”

The news reporters obtained a quote from the research from the Institute of Biomembranes, “Yeast, normal prostate cells and castration-resistant prostate cancer cells were treated with 6-TG or its analogues, in presence or absence of paclitaxel, or with olaparib, a poly-(ADP-ribose) polymerase (PARP) inhibitor currently in clinical trials for treatment of metastatic castration-resistant prostate cancer, and cell proliferation, apoptosis and androgen receptor (AR) levels were measured. 6-TG inhibited cell proliferation in yeast, normal and castration-resistant prostate cancer cells but promoted apoptosis only in cancer cells. Suppression of BRCA2 expression by siRNA or shRNA increased the sensitivity to 6-TG-and olaparib-induced apoptosis but did not affect cancer cell response to taxane. Intriguingly, 6-TG reduced AR expression levels independently on BRCA2 expression. Instead, olaparib decreased AR levels only in BRCA2-knockdown prostate cancer cells. Notably, overexpression of BRCA2 resulted in resistance of castration-resistant prostate cancer cells to 6-TG-, taxane-and olaparib-based treatment but promoted sensitivity to apoptosis induced by 2-amino-6-bromopurine and 2,6-dithiopurine, two 6-TG analogues.”

According to the news reporters, the research concluded: “Our results provide a pre-clinical rationale for the use of 6-TG in the treatment of BRCA2-deficient castration-resistant prostate cancers, and of certain 6-TG analogues for treatment of BRCA2-proficient prostate cancers.”

For more information on this research see: 6-Thioguanine and Its Analogs Promote Apoptosis of Castration-Resistant Prostate Cancer Cells in a BRCA2-Dependent Manner. Cancers, 2019;11(7):945.

Our news correspondents report that additional information may be obtained by contacting L. Moro, Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, National Research Council, Via Amendola 122, O, 70126 Bari, Italy. Additional authors for this research include N. Guaragnella, S. Giannattasio and L. Moro.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.3390/cancers11070945. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Places

Southern Europe
Italy
Europe
Bari

Subjects

Science and Technology
      Scientific Research
      Technology
            Applied Biotechnology
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer